Extended Data Fig. 8: Oligomycin and FCCP decrease NLRP3 inflammasome activation.
From: Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation
a) OCR in BMDMs from WT mice after one-hour treatment with or without oligomycin (50 nM) (N = 4, each treatment). b) Il1b mRNA expression (ΔΔCt) in BMDMs treated with or without LPS (100 ng/mL) for 4 hours with or without oligomycin (50 nM) (N = 5 for each treatment). c) Pro-IL-1β protein expression in cell lysates from BMDMs treated with LPS (100 ng/mL) for 5.5 hours, with or without oligomycin (50 nM). (N = 8 for each treatment). d) IL-1β protein levels in cell culture supernatant of BMDMs treated with LPS (100 ng/mL) and ATP (5 mM), with or without oligomycin (50 nM). (N = 6 for each condition). e) Intracellular caspase-1 protein expression in cell lysates from from BMDMs treated with LPS (100 ng/mL) and ATP (5 mM), with or without oligomycin (50 nM). (N = 6 for each condition). f) Intracellular pro-caspase-1 protein expression in cell lysates from BMDMs treated as in e. (N = 6 for each condition). g) Il1b mRNA expression (ΔΔCt) in BMDMs treated with or without LPS (100 ng/mL) for 4 hours with or without FCCP (10μM) (N = 5 for each condition). h) Pro-IL-1β protein expression in cell lysates from BMDMs treated with LPS (100 ng/mL) for 5.5 hours, with or without FCCP (10μM). (N = 5 for each treatment). i) IL-1β protein levels in cell culture supernatant of BMDMs treated with LPS (100 ng/mL) and ATP (5 mM), with or without FCCP (10μM). (N = 6 for both treatments). j) Intracellular caspase-1 (p20 fragment) protein expression in cell lysates from BMDMs treated with LPS (100 ng/mL) and ATP (5 mM), with or without FCCP (10μM). (N = 6 for all treatments). Data are means + /− SEM. *p < 0.05, two-tailed t-test (a *p = 0.0328; d *p < 0.0001; i *p = 0.0077), one-way ANOVA with Tukey test for multiple comparisons (e *p = 0.0026; j *p = 0.0041).
